Logo image of LYEL

LYELL IMMUNOPHARMA INC (LYEL) Stock Fundamental Analysis

USA - NASDAQ:LYEL - US55083R2031 - Common Stock

17.93 USD
+0.51 (+2.93%)
Last: 11/18/2025, 8:23:18 PM
Fundamental Rating

3

LYEL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. LYEL has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, LYEL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LYEL has reported negative net income.
LYEL had a negative operating cash flow in the past year.
LYEL had negative earnings in each of the past 5 years.
LYEL had a negative operating cash flow in each of the past 5 years.
LYEL Yearly Net Income VS EBIT VS OCF VS FCFLYEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

LYEL's Return On Assets of -85.98% is on the low side compared to the rest of the industry. LYEL is outperformed by 71.48% of its industry peers.
LYEL has a Return On Equity of -110.86%. This is comparable to the rest of the industry: LYEL outperforms 42.21% of its industry peers.
Industry RankSector Rank
ROA -85.98%
ROE -110.86%
ROIC N/A
ROA(3y)-40.23%
ROA(5y)-33.08%
ROE(3y)-49.13%
ROE(5y)-40.55%
ROIC(3y)N/A
ROIC(5y)N/A
LYEL Yearly ROA, ROE, ROICLYEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LYEL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYEL Yearly Profit, Operating, Gross MarginsLYEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K -500K

More info and screens

7

2. Health

2.1 Basic Checks

LYEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
LYEL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LYEL has more shares outstanding
There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LYEL Yearly Shares OutstandingLYEL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M
LYEL Yearly Total Debt VS Total AssetsLYEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

LYEL has an Altman-Z score of -3.99. This is a bad value and indicates that LYEL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.99, LYEL perfoms like the industry average, outperforming 43.53% of the companies in the same industry.
There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.99
ROIC/WACCN/A
WACC8.77%
LYEL Yearly LT Debt VS Equity VS FCFLYEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 7.65 indicates that LYEL has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.65, LYEL is doing good in the industry, outperforming 72.42% of the companies in the same industry.
A Quick Ratio of 7.65 indicates that LYEL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.65, LYEL is in the better half of the industry, outperforming 72.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.65
Quick Ratio 7.65
LYEL Yearly Current Assets VS Current LiabilitesLYEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

LYEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.47%, which is quite good.
The Revenue has been growing slightly by 1.69% in the past year.
The Revenue for LYEL have been decreasing by -37.89% on average. This is quite bad
EPS 1Y (TTM)12.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.72%
Revenue 1Y (TTM)1.69%
Revenue growth 3Y-82.11%
Revenue growth 5Y-37.89%
Sales Q2Q%-38.46%

3.2 Future

Based on estimates for the next years, LYEL will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.06% on average per year.
The Revenue is expected to grow by 439.98% on average over the next years. This is a very strong growth
EPS Next Y25.91%
EPS Next 2Y13.57%
EPS Next 3Y12.06%
EPS Next 5YN/A
Revenue Next Year-52.27%
Revenue Next 2Y-41.42%
Revenue Next 3Y454.46%
Revenue Next 5Y439.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LYEL Yearly Revenue VS EstimatesLYEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 20M 40M 60M 80M 100M
LYEL Yearly EPS VS EstimatesLYEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LYEL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LYEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYEL Price Earnings VS Forward Price EarningsLYEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYEL Per share dataLYEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

LYEL's earnings are expected to grow with 12.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.57%
EPS Next 3Y12.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LYEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LYELL IMMUNOPHARMA INC

NASDAQ:LYEL (11/18/2025, 8:23:18 PM)

17.93

+0.51 (+2.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07
Earnings (Next)N/A N/A
Inst Owners40.92%
Inst Owner Change-35.26%
Ins Owners0.58%
Ins Owner Change0.9%
Market Cap344.44M
Revenue(TTM)60.00K
Net Income(TTM)-331.40M
Analysts47.5
Price Target14.28 (-20.36%)
Short Float %1.23%
Short Ratio3.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.26%
Min EPS beat(2)3.59%
Max EPS beat(2)20.93%
EPS beat(4)3
Avg EPS beat(4)6.46%
Min EPS beat(4)-15.34%
Max EPS beat(4)20.93%
EPS beat(8)6
Avg EPS beat(8)9.38%
EPS beat(12)10
Avg EPS beat(12)19.12%
EPS beat(16)13
Avg EPS beat(16)18.05%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)27.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)27.27%
EPS NY rev (1m)3.68%
EPS NY rev (3m)25.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)23.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5740.59
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-13.83
EYN/A
EPS(NY)-11.22
Fwd EYN/A
FCF(TTM)-10.59
FCFYN/A
OCF(TTM)-8.93
OCFYN/A
SpS0
BVpS15.56
TBVpS15.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.98%
ROE -110.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.23%
ROA(5y)-33.08%
ROE(3y)-49.13%
ROE(5y)-40.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 195.7%
Cap/Sales 53105%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.65
Quick Ratio 7.65
Altman-Z -3.99
F-Score3
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)103.35%
Cap/Depr(5y)398.19%
Cap/Sales(3y)18080.8%
Cap/Sales(5y)11104.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.72%
EPS Next Y25.91%
EPS Next 2Y13.57%
EPS Next 3Y12.06%
EPS Next 5YN/A
Revenue 1Y (TTM)1.69%
Revenue growth 3Y-82.11%
Revenue growth 5Y-37.89%
Sales Q2Q%-38.46%
Revenue Next Year-52.27%
Revenue Next 2Y-41.42%
Revenue Next 3Y454.46%
Revenue Next 5Y439.98%
EBIT growth 1Y4.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.14%
EBIT Next 3Y-13.58%
EBIT Next 5YN/A
FCF growth 1Y-17.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.37%
OCF growth 3YN/A
OCF growth 5YN/A

LYELL IMMUNOPHARMA INC / LYEL FAQ

What is the ChartMill fundamental rating of LYELL IMMUNOPHARMA INC (LYEL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to LYEL.


Can you provide the valuation status for LYELL IMMUNOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to LYELL IMMUNOPHARMA INC (LYEL). This can be considered as Overvalued.


How profitable is LYELL IMMUNOPHARMA INC (LYEL) stock?

LYELL IMMUNOPHARMA INC (LYEL) has a profitability rating of 0 / 10.


How financially healthy is LYELL IMMUNOPHARMA INC?

The financial health rating of LYELL IMMUNOPHARMA INC (LYEL) is 7 / 10.


Can you provide the expected EPS growth for LYEL stock?

The Earnings per Share (EPS) of LYELL IMMUNOPHARMA INC (LYEL) is expected to grow by 25.91% in the next year.